secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001104659-22-113204
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit
--------------------------------------------------------------------------------

- ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.
- Total revenue $99.1M, including $65.7M from vixarelimab license with Genentech.
- Net income $224.1M vs net loss $30.5M YoY; includes $177.4M tax benefit from valuation allowance release.
- Cash and equivalents $200.7M, no debt; expected to fund operations into at least 2025.
- RHAPSODY LTE data: rilonacept beyond 18 months reduced recurrence risk 98.2% (HR=0.018, p<0.0001).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/0001104659-22-113204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/tm2229208d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-113204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer